SDZ 216-525

SDZ 216-525 is a serotonergic drug derived from the phenylpiperazine family which is used in scientific research. It acts as a potent and selective 5-HT_1A receptor antagonist, and is used for research into the function of the 5-HT_1A receptor.^[1]^[2]^[3]^[4]^[5]^[6]

Other namesSDZ-216525; SDZ216525; SDZ216-525

Drug classSerotonin 5-HT_1A receptor antagonist

ATC code

None

CAS Number

141533-35-9^Y

Quick facts Clinical data, Other names ...

SDZ 216-525
Clinical data

Other names	SDZ-216525; SDZ216525; SDZ216-525
Drug class	Serotonin 5-HT_1A receptor antagonist
ATC code	None
Identifiers
IUPAC name methyl 4-[4-[4-(1,1,3-trioxo-1,2-benzothiazol-2-yl)butyl]piperazin-1-yl]-1H-indole-2-carboxylate
CAS Number	141533-35-9^Y
PubChem CID	3037456
Chemical and physical data
Formula	C₂₅H₂₈N₄O₅S
Molar mass	496.58 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COC(=O)C1=CC2=C(N1)C=CC=C2N3CCN(CC3)CCCCN4C(=O)C5=CC=CC=C5S4(=O)=O
InChI InChI=1S/C25H28N4O5S/c1-34-25(31)21-17-19-20(26-21)8-6-9-22(19)28-15-13-27(14-16-28)11-4-5-12-29-24(30)18-7-2-3-10-23(18)35(29,32)33/h2-3,6-10,17,26H,4-5,11-16H2,1H3 Key:LPPRLWFUMJHAKF-UHFFFAOYSA-N

References

[1]
Schoeffter P, Fozard JR, Stoll A, Siegl H, Seiler MP, Hoyer D (February 1993). "SDZ 216-525, a selective and potent 5-HT1A receptor antagonist". European Journal of Pharmacology. 244 (3): 251–257. doi:10.1016/0922-4106(93)90150-8. PMID 8384569.
[2]
Millan MJ, Rivet JM, Canton H, Le Marouille-Girardon S, Gobert A (March 1993). "Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists". The Journal of Pharmacology and Experimental Therapeutics. 264 (3): 1364–1376. doi:10.1016/S0022-3565(25)10153-5. PMID 8450471.
[3]
Lanfumey L, Haj-Dahmane S, Hamon M (November 1993). "Further assessment of the antagonist properties of the novel and selective 5-HT1A receptor ligands (+)-WAY 100 135 and SDZ 216-525". European Journal of Pharmacology. 249 (1): 25–35. doi:10.1016/0014-2999(93)90658-5. PMID 8282017.
[4]
Routledge C, Hartley J, Gurling J, Ashworth-Preece M, Brown G, Dourish CT (1994). "In vivo characterization of the putative 5-HT1A receptor antagonist SDZ 216,525 using two models of somatodendritic 5-HT1A receptor function". Neuropharmacology. 33 (3–4): 359–366. doi:10.1016/0028-3908(94)90066-3. PMID 7984274.
[5]
Schreiber R, Brocco M, Lefèbvre de Ladonchamps B, Monneyron S, Millan MJ (November 1995). "A drug discrimination analysis of the actions of novel serotonin1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin". The Journal of Pharmacology and Experimental Therapeutics. 275 (2): 822–831. doi:10.1016/S0022-3565(25)12134-4. PMID 7473172.
[6]
Cao BJ, Rodgers RJ (October 1997). "Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190". Pharmacology, Biochemistry, and Behavior. 58 (2): 593–603. doi:10.1016/s0091-3057(97)00279-7. PMID 9300624.

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

See also

References

Related Articles